에 대한 최신 뉴스 Sotera Health (NASDAQ:SHC) 주식

Sotera Health

Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe and other regions.

Sotera Health Co

Sharp Corp

Shi Corp

SEARCH MINERALS INC ORD by Search Minerals, Inc.

Search Minerals Inc

Soho House & Co Inc. Class A Common Stock

Soho House & Co Inc

SHARECARE INC CL A

SHARECARE INC RED WT EXP

NVEE

Upon Closing Of The Transaction, Current Acuren Stockholders Will Own ~60%, And Current NV5 Stockholders Will Own ~40% Of The Combined Company

Earnings

News

Walmart Q1 Revenue Of $165.6B Includes ~100 Bps Headwind From Lapping Leap Day

Tom Lee, co-founder and research head at&nbsp;Fundstrat Global Advisors, expressed optimism about the current market scenario, notwithstanding the recent volatility.
What Happened: Lee identified&nbsp;key indicators suggesting that the&nbsp;worst market decline may have passed and predicted a significant upside for stocks by 2026.&nbsp;On the Global Money Talk podcast on Tuesday, he emphasized that&nbsp;the recovery of 50% of&nbsp;the market&#8217;s losses, which took place the previous Friday, is a strong indication&nbsp;that the market may have&nbsp;reached its lowest point. 
He also observed that the high-yield bond market, a leading indicator for equities, has recovered 50% of its losses, further reinforcing the possibility of a stock market rebound. Lee advised investors to steer clear of decisions based on daily news cycles and instead concentrate on the potential for 2026 earnings to surpass expectations.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Markets Look Scary? Tom Lee Says $7 Trillion Is Ready to Buy &#x7C; Tom Lee, Fundstrat" width="500" height="281" src="https://www.youtube.com/embed/kCh2R5eEoL0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Despite the ongoing tariff war, Lee is confident that the U.S.&#8217;s&nbsp;potential for upside in exports,&nbsp;deregulation, and tax policy incentives could propel&nbsp;earnings growth and price-to-earnings (P/E)&nbsp;multiple expansion, creating a favorable&nbsp;environment for stocks.
Lee also mentioned that a trade-related recession is already in progress, but it is unlikely to instigate a full-blown U.S. recession unless paired with a significant shock. He dismissed the calls for a full-blown imminent recession and stated, &#8220;..for someone to be so confident that we're going to have a recession, I think they're dead wrong.&#8221; He also notes that many economists frequently struggle to accurately identify when recessions are actually occurring. &#8220;In my 30 years, I've never seen an economist get the recession right,&#8221; added Lee.
He keeps a close eye on&nbsp;the high-yield bond market, where&nbsp;spreads currently sit at 367 basis points—well&nbsp;below the 1,000 basis points&nbsp;that typically indicate an imminent recession. Lee also highlighted the $7 trillion in cash sitting on the sidelines.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45426516/chuck-schumer-says-trump-is-letting-cartel-members-into-the-us-asks-how-much-memecoin-did-" target="_blank" rel="noreferrer noopener">Chuck Schumer Says Trump Is &#8216;Letting Cartel Members&#8217; Into The US, Asks How Much &#8216;Memecoin&#8217; Did They Pay</a>
Why It Matters: Lee&#8217;s optimism comes after he previously <a href="https://www.benzinga.com/markets/25/04/44685594/tom-lee-predicts-a-v-shaped-recovery-for-us-stocks-pins-hope-on-trump-put-its-going-to-take-a-little-time">underestimated </a>the impact of tariffs on the market, which he likened to a &#8220;heart attack&#8221; for both the stock market and the broader economy. He predicted a V-shaped recovery and later urged Treasury Secretary Scott Bessent and Commerce Secretary Howard Lutnick to expedite trade deals for a positive &#8220;policy shock&#8221; to the stock markets.
Lee&#8217;s current outlook aligns with major brokerages such as Goldman Sachs, Barclays and J.P. Morgan, who have revised their U.S. recession forecasts <a href="https://www.benzinga.com/markets/25/05/45401678/goldman-sachs-barclays-jpm-walk-back-us-recession-forecasts-after-90-day-us-china-tariff-truce-fewer-fed-cuts-expected-in-2025">following </a>a 90-day tariff truce between the U.S. and China. Meanwhile, analysts like Jim Cramer believe that a &#8220;steady drip of trade deals&#8221; is essential for strengthening the market and easing recession concerns.
Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) soared more than 13%, while SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) surged 9.30% over the past month.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/05/45314762/charlie-munger-was-once-asked-why-warren-buffett-was-so-much-richer-and-replied-he-got-an-earlier-start-before-adding-why-was-albert-einstein-poorer-than-i-was" target="_blank" rel="noreferrer noopener">Charlie Munger Was Once Asked Why Warren Buffett Was So Much Richer — He Replied, &#8216;He Got An Earlier Start,&#8217; Then Added, &#8216;Why Was Albert Einstein Poorer Than I Was?&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Economics

General

Fundstrat's Tom Lee Says Economists Predicting A Recession With Certainty Are 'Dead Wrong': 'In My 30 Years, I've Never Seen...'

Needham analyst Serge Belanger maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and lowers the price target from $4 to $3.

Price Target

Analyst Ratings

CLSD

Needham Maintains Buy on Clearside Biomedical, Lowers Price Target to $3

Earnings Misses

POAI

Predictive Oncology Q1 EPS $(0.34) Misses $(0.09) Estimate, Sales $110.00

Acuren And NV5 Announce Merger Agreement, Under Which NV5 Stockholders Will Receive $23/Share Consisting Of $10 In Cash And $12 In Acuren Shares For Total Consideration ~$1.7B; Deal Expected To Be Immediately Accretive To Acuren

Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) reported quarterly losses of $(0.14) per share. This is a 63.16 percent increase over losses of $(0.38) per share from the same period last year. The company reported $11.30 million in sales this quarter.

IVVD

Invivyd Q1 EPS $(0.14) Up From $(0.38) YoY, Sales $11.30M Up from 0 YoY

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="6">Second quarter</td>
<td colspan="3">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
</tr>
<tr>
<td colspan="3">&nbsp;</td>
<td colspan="6">The Company's second quarter fiscal 2026 guidance is based on Q2 FY25 net sales of $167.8 billion.</td>
<td colspan="3">&nbsp;</td>
</tr>
<tr>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
</tr>
<tr>
<td colspan="3">&nbsp;</td>
<td colspan="3">Consolidated metric</td>
<td colspan="3">Q2 FY26</td>
<td colspan="3">&nbsp;</td>
</tr>
<tr>
<td colspan="3">&nbsp;</td>
<td colspan="3">Net sales (cc)</td>
<td colspan="3">
Increase 3.5% to 4.5%
•Including approximately 20 bps tailwind from acquisition of VIZIO
</td>
<td colspan="3">&nbsp;</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Walmart Sees Q2 Sales $173.673B-$175.350B vs $175.21B Est

Bragg Gaming Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BRAG#TSX">BRAG</a>) reported quarterly losses of $(0.11) per share. This is a 37.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $25.50 million in sales this quarter. This is a 7.11 percent increase over sales of $23.81 million the same period last year.

TSX:BRAG

Bragg Gaming Group Q1 EPS Euros(0.11) Down From $(0.08) YoY, Sales Euros25.50M Up From Euros23.81M YoY

Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) reported quarterly losses of $(15.96) per share which missed the analyst consensus estimate of $(14.08) by 13.35 percent. This is a 13.64 percent increase over losses of $(18.48) per share from the same period last year. The company reported quarterly sales of $13.64 million which missed the analyst consensus estimate of $13.99 million by 2.49 percent. This is a 21.95 percent decrease over sales of $17.48 million the same period last year.

VERO

Venus Concept Q1 Adj. EPS $(15.96) Misses $(14.08) Estimate, Sales $13.64M Miss $13.99M Estimate

Bragg Gaming Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRAG#NASDAQ">BRAG</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.01) by 1100 percent. This is a 33.33 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $26.82 million which beat the analyst consensus estimate of $26.75 million by 0.28 percent. This is a 3.72 percent increase over sales of $25.86 million the same period last year.

Earnings Beats

BRAG

Bragg Gaming Group Q1 EPS $(0.12) Misses $(0.01) Estimate, Sales $26.82M Beat $26.75M Estimate

Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a 18.75 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $2.75 million which missed the analyst consensus estimate of $5.84 million by 52.84 percent. This is a 70.21 percent decrease over sales of $9.24 million the same period last year.

MRSN

Mersana Therapeutics Q1 EPS $(0.19), Inline, Sales $2.75M Miss $5.84M Estimate

<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td colspan="3">Fiscal year 2026</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td colspan="3">The Company's fiscal year guidance is based on the following FY25 figures: Net sales: $674.5 billion, adjusted operating income1: $29.5 billion, and adjusted EPS1: $2.51.</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Consolidated metric</td>
<td>Original from 2.20.2025</td>
<td>As of 5.15.2025</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Net sales (cc)</td>
<td>
Increase 3.0% to 4.0%
•Including approximately 20 bps headwind from lapping leap year
•Including approximately 20 bps tailwind from acquisition of VIZIO
</td>
<td>Unchanged</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Adj. operating income (cc)</td>
<td>
Increase 3.5% to 5.5%
•Including approximately 70 bps headwind from lapping leap year
•Including approximately 80 bps headwind from acquisition of VIZIO
</td>
<td>Unchanged</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Interest, net</td>
<td>Increase approximately $100M to $200M</td>
<td>Unchanged</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Effective tax rate</td>
<td>Approximately 23.5% to 24.5%</td>
<td>Unchanged</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Non-controlling interest</td>
<td>Relatively flat</td>
<td>Unchanged</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Adjusted EPS</td>
<td>$2.50 to $2.60, including approximately $0.05 headwind from currency</td>
<td>Unchanged</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Capital expenditures</td>
<td>Approximately 3.0% to 3.5% of net sales</td>
<td>Unchanged</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Walmart Affirms FY2026 Adj EPS Guidance of $2.50-$2.60 vs $2.61 Est; Affirms FY2026 Sales Guidance of $694.74B-$701.48B vs $705.33B Est

Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.72) by 28.49 percent. This is a 531.43 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $29.00 thousand which missed the analyst consensus estimate of $5.00 million by 99.42 percent. This is a 99.84 percent decrease over sales of $17.58 million the same period last year.

DTIL

Precision BioSciences Q1 EPS $(2.21) Misses $(1.72) Estimate, Sales $29.00K Miss $5.00M Estimate

GAMB

Gambling.com Gr Affirms FY2025 Sales Guidance of $170.00M-$174.00M vs $172.31M Est

REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.97) by 17.53 percent. This is a 74.6 percent increase over losses of $(3.15) per share from the same period last year. The company reported $12.00 thousand in sales this quarter. This is a 97.36 percent decrease over sales of $455.00 thousand the same period last year.

REE Automotive Q4 Adj. EPS $(0.80) Beats $(0.97) Estimate, Sales $12.00K Down From $455.00K YoY

Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) reported quarterly losses of $(4.68) per share which missed the analyst consensus estimate of $(3.44) by 36.05 percent. This is a 81.28 percent increase over losses of $(25.00) per share from the same period last year. The company reported quarterly sales of $640.92 thousand which missed the analyst consensus estimate of $2.35 million by 72.73 percent. This is a 52.13 percent decrease over sales of $1.34 million the same period last year.

WKHS

Workhorse Gr Q1 EPS $(4.68) Misses $(3.44) Estimate, Sales $640.92K.

Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.90 by 1.11 percent. This is a 31.88 percent increase over earnings of $0.69 per share from the same period last year. The company reported quarterly sales of $467.30 million which beat the analyst consensus estimate of $458.60 million by 1.90 percent. This is a 27.75 percent increase over sales of $365.80 million the same period last year.

Marex Group Q1 Adj. EPS $0.91 Beats $0.90 Estimate, Sales $467.30M Beat $458.60M Estimate

Walmart Q1 US Comp Sales +4.5%

American Shared Hospital (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMS#AMEX">AMS</a>) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $0.04 by 350 percent. This is a 600 percent decrease over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $6.11 million which missed the analyst consensus estimate of $8.63 million by 29.18 percent. This is a 17.18 percent increase over sales of $5.22 million the same period last year.

American Shared Hospital Q1 EPS $(0.10) Misses $0.04 Estimate, Sales $6.11M Miss $8.63M Estimate

Press Releases

Sotera Health to Share Next Chapter of Growth at 2024 Investor Day

Firstlight Management Calls on the Board of Directors of Sotera Health Company to Launch Sale Process for Nelson Labs

Management

Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

Sotera Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Sotera Health Chairman and CEO Presents at 43rd Annual J.P. Morgan Healthcare Conference

Sotera Health Announces Fourth-Quarter and Full-Year 2024 Earnings Release Date

Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provides 2025 Outlook

Health Care

Nelson Labs Launches Innovative Rapid Sterility Testing to Significantly Expedite Product Sterility Results

Sotera Health Announces First-Quarter 2025 Earnings Release Date

Sotera Health Reports First-Quarter 2025 Results

TYO:1223

TYO:71

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Sotera Health

뉴스

에 대한 최신 뉴스 Sotera Health (NASDAQ:SHC) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌